A multi-centre, randomised, single-blind, placebo-controlled, parallel group study to investigate the efficacy of single pre-emptive doses of GW842166X, a non-cannabinoid CB2 [cannabinoid] receptor agonist, on pain following third molar tooth extraction
Latest Information Update: 18 Sep 2021
At a glance
- Drugs GW 842166X (Primary) ; Ibuprofen (Primary)
- Indications Dental pain; Postoperative pain
- Focus Pharmacogenomic; Therapeutic Use
- 01 Nov 2012 Planned patient number is 120 according to European Clinical Trials Database record.
- 18 May 2009 Biomarkers information updated
- 18 Sep 2008 Actual patient number (112) added as reported by ClinicalTrials.gov.